Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction

Abstract

Esophageal adenocarcinoma (EAC) and adenocarcinoma of the esophagogastric junction (EGJA) have long been associated with poor prognosis. With changes in the spectrum of the disease caused by economic development and demographic changes, the incidence of EAC and EGJA continues to increase, making them worthy of more attention from clinicians. For a long time, surgery has been the mainstay treatment for EAC and EGJA. With advanced techniques, endoscopic therapy, radiotherapy, chemotherapy, and other treatment methods have been developed, providing additional treatment options for patients with EAC and EGJA. In recent decades, the emergence of multidisciplinary therapy (MDT) has enabled the comprehensive treatment of tumors and made the treatment more flexible and diversified, which is conducive to achieving standardized and individualized treatment of EAC and EGJA to obtain a better prognosis. This review discusses recent advances in EAC and EGJA treatment in the surgical-centered MDT mode in recent years.

Effect of two surgical approaches on the lung function and prognosis of patients with combined esophagogastric cancer

“…Current clinical studies on the treatment of combined esophagogastric cancer mainly compare the efficacies and adverse effects of the different approaches[ 24 - 27 ]; they less frequently focus on the changes in the parameters of pulmonary function. In this study, the clinical outcomes, lymph node removal, and lung function recovery of patients with combined oesophagogastric cancer treated using transabdominal and transthoracic surgical approaches were studied comprehensively.…”

Decoding common genetic alterations between Barrett's esophagus and esophageal adenocarcinoma: A bioinformatics analysis

“…Esophageal adenocarcinoma (EAC) and squamous cell carcinoma are two main subtypes of esophagus cancers. EAC is the predominant subtype in Western countries and has increased dramatically by six folds during the past three decades, more than any cancer type [ 1 , 2 ]. EAC is responsible for two-thirds of esophageal cancer cases in high-income countries, with overweighting, gastric-esophageal reflux (GERD), and Barret's esophagus (BE) as its major contributors.…”

The development and validation of automated machine learning models for predicting lymph node metastasis in Siewert type II T1 adenocarcinoma of the esophagogastric junction

“…Due to its particular anatomical location, the treatment of Siewert type II AEG has been historically complicated. For locally advanced tumors, radical surgical resection is still the primary treatment for AEG ( 5 , 11 ). However, with gastrointestinal endoscopy screening, patients with digestive tract cancer are diagnosed at an early stage, making it possible to treat early AEG without lymphatic and organ metastasis by endoscopy.…”

“…The global incidence of adenocarcinoma of the esophagogastric junction (AEG) has been rapidly increasing (1)(2)(3)(4)(5)(6)(7). The incidence of AEG increased by 2.5 times between 1973 and 1992, according to the statistics from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program (4).…”